JP7594439B2 - 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用 - Google Patents

主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用 Download PDF

Info

Publication number
JP7594439B2
JP7594439B2 JP2020544370A JP2020544370A JP7594439B2 JP 7594439 B2 JP7594439 B2 JP 7594439B2 JP 2020544370 A JP2020544370 A JP 2020544370A JP 2020544370 A JP2020544370 A JP 2020544370A JP 7594439 B2 JP7594439 B2 JP 7594439B2
Authority
JP
Japan
Prior art keywords
cells
mhc
car
seq
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020544370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502122A5 (https=
JP2021502122A (ja
Inventor
ノーヴィル，ジュリー
ウッド，エリザベス
Original Assignee
ジュラ バイオ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジュラ バイオ，インコーポレイテッド filed Critical ジュラ バイオ，インコーポレイテッド
Publication of JP2021502122A publication Critical patent/JP2021502122A/ja
Publication of JP2021502122A5 publication Critical patent/JP2021502122A5/ja
Priority to JP2024203947A priority Critical patent/JP2025019209A/ja
Application granted granted Critical
Publication of JP7594439B2 publication Critical patent/JP7594439B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/48—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020544370A 2017-11-10 2018-11-10 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用 Active JP7594439B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024203947A JP2025019209A (ja) 2017-11-10 2024-11-22 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584449P 2017-11-10 2017-11-10
US62/584,449 2017-11-10
PCT/US2018/060227 WO2019094847A1 (en) 2017-11-10 2018-11-10 Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024203947A Division JP2025019209A (ja) 2017-11-10 2024-11-22 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用

Publications (3)

Publication Number Publication Date
JP2021502122A JP2021502122A (ja) 2021-01-28
JP2021502122A5 JP2021502122A5 (https=) 2021-12-23
JP7594439B2 true JP7594439B2 (ja) 2024-12-04

Family

ID=66438683

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544370A Active JP7594439B2 (ja) 2017-11-10 2018-11-10 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用
JP2024203947A Pending JP2025019209A (ja) 2017-11-10 2024-11-22 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024203947A Pending JP2025019209A (ja) 2017-11-10 2024-11-22 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用

Country Status (10)

Country Link
US (2) US11826385B2 (https=)
EP (1) EP3707247A4 (https=)
JP (2) JP7594439B2 (https=)
KR (2) KR20250067182A (https=)
CN (2) CN111373031A (https=)
AU (2) AU2018365080B2 (https=)
CA (1) CA3081583A1 (https=)
IL (2) IL310483B2 (https=)
SG (1) SG11202004202QA (https=)
WO (1) WO2019094847A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081764A1 (en) * 2018-10-18 2020-04-23 Synerk Inc. Compositions and methods for inhibiting tigit gene expression
JP2022533713A (ja) 2019-05-21 2022-07-25 サンガモ セラピューティクス， インコーポレイテッド 調節性ｔ細胞における制御された導入遺伝子発現
CN110257376A (zh) * 2019-06-03 2019-09-20 上海长海医院 一种CRISPR/Cas9基因编辑方法敲除角质形成细胞中PD-L1基因的方法
WO2021007580A1 (en) 2019-07-11 2021-01-14 Valkyr, Inc. System and methods relating to chimeric autoantibody receptors
CN110872577B (zh) * 2020-01-20 2020-05-08 中国科学院动物研究所 修饰的免疫细胞及其应用
US20210268023A1 (en) * 2020-03-01 2021-09-02 The Trustees Of Columbia University In The City Of New York Enhanced CAR Tregs and Bi-Specific Antibodies for Induction of Immune Tolerance, Treating Autoimmune Diseases and Preventing Transplantation Rejection
WO2022165419A1 (en) * 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
EP4039808A1 (en) * 2021-02-08 2022-08-10 Ospedale San Raffaele S.r.l. Guide rnas and uses thereof
US12577290B2 (en) 2021-03-04 2026-03-17 Allogene Therapeutics, Inc. FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
CN117715929A (zh) * 2021-07-29 2024-03-15 南特细胞公司 用于预防和治疗病毒感染和癌症的经修饰的t细胞受体
US20240360198A1 (en) * 2021-09-01 2024-10-31 National University Corporation Kanazawa University Immunoregulatory method, nucleic acid composition for immunoregulation, and use thereof
EP4453021A4 (en) * 2021-12-22 2025-12-31 Memorial Sloan Kettering Cancer Center CELLS EXPRESSING FAS LIGAND POLYPEPTIDES AND FAS INACTIVATION AND THEIR USES
US20250304913A1 (en) * 2022-04-06 2025-10-02 The Regents Of The University Of Colorado, A Body Corporate Chimeric antigen receptor t cells and methods of use thereof
WO2023235856A1 (en) * 2022-06-03 2023-12-07 Jura Bio, Inc Apoptosis resistant immune cells with major histocompatibility complex chimeric antigen receptor
CN116284447A (zh) * 2023-02-20 2023-06-23 苏州大学 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用
NL2037452B1 (en) * 2024-04-12 2025-11-03 Academisch Ziekenhuis Leiden Agents for treating Celiac Disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151860A0 (en) * 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
IL136511A0 (en) * 2000-06-01 2001-06-14 Gavish Galilee Bio Appl Ltd Genetically engineered mhc molecules
ATE509025T1 (de) * 2002-06-12 2011-05-15 Gavish Galilee Bio Appl Ltd ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß
US20080286312A1 (en) * 2002-06-12 2008-11-20 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
EP2331566B1 (en) * 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2632955A1 (en) * 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
EP3013361B1 (en) 2013-06-24 2021-10-06 NexImmune, Inc. Compositions and methods for immunotherapy
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
WO2015179801A1 (en) 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
TWI751102B (zh) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
CA2972714A1 (en) * 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
EP3569244A1 (en) * 2015-09-23 2019-11-20 CytoImmune Therapeutics, LLC Flt3 directed car cells for immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Blood，2012年，Vol. 119，p. 3940-3950
J. Immunol.，2008年，Vol. 180，p. 3601-3611
Proc. Natl. Acad. Sci. USA，2009年，Vol. 106，p. 3360-3365

Also Published As

Publication number Publication date
EP3707247A1 (en) 2020-09-16
IL274239B2 (en) 2024-07-01
KR20250067182A (ko) 2025-05-14
AU2018365080A1 (en) 2020-05-07
AU2025252604A1 (en) 2025-11-06
EP3707247A4 (en) 2021-11-03
IL274239A (en) 2020-06-30
US20240165158A1 (en) 2024-05-23
US11826385B2 (en) 2023-11-28
CA3081583A1 (en) 2019-05-16
KR102802061B1 (ko) 2025-05-02
IL310483B1 (en) 2024-11-01
IL310483A (en) 2024-03-01
WO2019094847A1 (en) 2019-05-16
KR20200079507A (ko) 2020-07-03
CN111373031A (zh) 2020-07-03
US20210169929A1 (en) 2021-06-10
JP2021502122A (ja) 2021-01-28
SG11202004202QA (en) 2020-06-29
JP2025019209A (ja) 2025-02-06
IL274239B1 (en) 2024-03-01
AU2018365080B2 (en) 2025-07-24
US12421293B2 (en) 2025-09-23
CN118530373A (zh) 2024-08-23
IL310483B2 (en) 2025-03-01

Similar Documents

Publication Publication Date Title
JP7594439B2 (ja) 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用
JP7657474B2 (ja) Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
JP2023029373A (ja) キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
JP7123794B2 (ja) 免疫細胞組成物及びそれを使用する方法
TWI841576B (zh) 用於治療傳染病之共受體系統
US20220016166A1 (en) T-cell expressing chimeric receptor
JP2021515598A (ja) 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法
US20260001934A1 (en) Compositions and methods of acetycholine receptor chimeric autoantibody receptor cells
WO2019154313A1 (zh) 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途
US20210214439A1 (en) Chimeric antigen receptors and gene editing of cd2 for immunotherapy of t-cell malignancies
US20240350632A1 (en) Engineered immune cells for treating disorders, compositions and methods thereof
US11613574B2 (en) Methods and compositions relating to ex vivo culture and modulation of T cells
AU2023288854A1 (en) Engineered human t cells comprising a switchable chimeric antigen cell surface receptor and methods for generating them
US20230277622A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS THEREOF
US20240360236A1 (en) Methods for targeted immunotherapy of acute myeloid leukemia (aml)
TW202611295A (zh) 表現ｉｌ－１０及嵌合抗原受體之ｃｄ４＋ｔ細胞及其用途
EP4602171A1 (en) Transduction of gammadelta t cells with pseudotyped retroviral vectors
WO2025212536A1 (en) Therapeutic antibody epitope-tagged car t cells for enhanced control and safety

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241122

R150 Certificate of patent or registration of utility model

Ref document number: 7594439

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150